Is compounded semaglutide safe? What FDA actually says, and what it does not

Compounded semaglutide is the same molecule as Wegovy and Ozempic, made by a licensed pharmacy rather than Novo Nordisk, and it is lawful. What it is not is FDA-approved: in FDA's words, the agency "does not review compounded drugs for safety, effectiveness or quality before they are marketed". FDA's published concerns are specific, and none of them is that the molecule is different. They are dosing errors from self-measured vials, products shipped warm, fraudulent labels naming pharmacies that never made them, and doses above the approved label. Each is checkable before you buy, and this page shows how.

Julian CaraulaniFounder, PriceTracker GLP-1Last checked Sep 3 · reviewed by Dr. A. Goher, MDWe track prices. Clinical facts on this site are quoted from the drug's label, the FDA or the published trial, with the source and the date beside each one. We do not write medical guidance and we do not tell anyone what to take.

11 min read · published Sep 3

The short version

1Same molecule, lawful, not FDA-approved: FDA does not review the finished product for safety, effectiveness or quality.
2FDA's stated concerns are about handling, not chemistry: dosing errors, warm shipping, fraudulent labels, off-label doses.
3Two kinds of compounder: 503A pharmacies overseen by state boards, 503B outsourcing facilities inspected by FDA to manufacturing standards.
4FDA's rule for multi-dose vials: discard 28 days after first use, whatever the compounder's label says.
5The risk lives in the seller, not the drug. Checking the pharmacy, the licence and the dosing is the whole job.

Both sides of this argument are selling something, so this page quotes the referee. Novo's line is that "Only Novo Nordisk manufactures FDA-approved semaglutide medicines".⁵ The telehealth industry's line is that it is the same molecule. Both are true, and neither answers the question. FDA has published exactly what concerns it about compounded GLP-1s, and the list is specific enough to act on. Here it is, item by item.

What "not FDA-approved" means, precisely

It does not mean illegal. Compounding is a lawful practice, and a licensed pharmacy may compound semaglutide for a patient with a prescription. What it means is narrower and worth stating in FDA's words: "unapproved versions do not undergo FDA's review for safety, effectiveness and quality before they are marketed".¹ Wegovy went through that review; the vial from a compounding pharmacy did not, and nobody at FDA has examined that specific preparation.

FDA's position on when that is acceptable is also on the record, and it is stricter than the industry's: "Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug", or when "the FDA-approved drug is not commercially available".¹ Price is not on that list. FDA does not consider "I cannot afford Wegovy" a medical need, and it is honest to say so, because that is the reason almost everyone on this site is buying compounded.

In plain English

So the true position is: lawful, same molecule, unreviewed, and used mostly for a reason FDA does not endorse. That is not a reason not to do it. It is the thing you are actually deciding.

Two kinds of compounder, and it matters which

FDA's own explainer draws a line most telehealth sites do not.⁴

	503A pharmacy	503B outsourcing facility
Overseen by	state boards of pharmacy	FDA, "inspected by FDA according to a risk-based schedule"
Manufacturing standard	not subject to CGMP	"subject to current good manufacturing practice (CGMP) requirements"
Makes drugs	per patient, per prescription	in batches, to a manufacturing standard

Neither is FDA-approved. But a 503B facility is FDA-inspected and held to the same manufacturing rules as a drug factory, and a 503A pharmacy is not. When a seller says its medication comes from an "FDA-registered" or "FDA-inspected" facility, this is the distinction it is pointing at, and it is worth asking a seller which kind it uses. Our seller check includes it.

FDA's concerns, itemised

This is the useful part. FDA's page on compounded GLP-1s does not say the molecule is wrong. It lists four practical failures it has received reports of.

1. Dosing errors from vials

Branded semaglutide comes in a pen that delivers a fixed dose. Compounded semaglutide usually comes in a vial you draw from with a syringe, measured in units, and this is where FDA has "received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors ... These dosing errors resulted from patients measuring and self-administering incorrect doses of the drug, and in some cases, health care professionals miscalculating doses".² A tenfold error is one decimal place on a syringe.

What to do: get the dose in milligrams and in units, in writing, from the prescriber, and confirm the vial's concentration matches the instructions before the first injection. If the seller cannot tell you the concentration in mg per mL, that is a reason to stop.

2. Doses beyond the label

FDA has also received reports "related to patients prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label", meaning more per dose, more often, or climbing faster.² The symptoms it lists are the gut effects, severe enough to seek care. There is no reason a compounded product should escalate faster than Wegovy's label, and a program that does is trading your stomach for its retention numbers.

What to do: compare the program's schedule to the semaglutide dose ladder. Four weeks per step is the label. Faster is not a feature.

3. Fraudulent products

FDA is aware of "fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label", including labels naming pharmacies that "do not exist" and labels naming "a licensed pharmacy that ... did not compound these products".³ This is the one concern that is about the drug itself: if the pharmacy on the label did not make it, nobody knows what is in the vial.

What to do: the label names a pharmacy. Look that pharmacy up in its state board's licence register, and if the seller will not say which pharmacy fills its prescriptions before you pay, do not pay.

4. Warm shipping

Semaglutide is refrigerated. FDA "has received complaints that certain compounded GLP-1 drugs have arrived warm or with inadequate ice packs", and its advice is not to use "any injectable GLP-1 drug that arrives warm or with insufficient refrigeration".³

What to do: if it arrives warm, it arrived spoiled. A reputable program replaces it without argument.

5. The 28-day rule

Multi-dose vials are the norm in compounding, and some compounders label them as usable for longer than FDA thinks is safe. FDA's instruction overrides the label: "Discard the vial within 28 days after the first use, even if medication remains in the vial. Do not continue using medication from the vial after 28 days, even if instructions from the compounder say the medication can be used for longer than 28 days."³ Sterile drugs contaminate after repeated needle entry, and 28 days is the line.

What FDA does not say

It does not say compounded semaglutide does not work. Same molecule, same receptor, and the trial evidence for the molecule applies at the same dose. It does not say the side effects differ; they are the drug's, not the maker's, and the label percentages in the side-effect guide are the honest expectation for either. And it does not say the products from licensed pharmacies are generally contaminated or mislabelled; its concern is that it has not checked, and that some sellers have exploited that.

The picture that leaves is precise: the molecule is the same, the process is unreviewed, and every documented harm on FDA's list comes from a step between the pharmacy and your arm. Which pharmacy, what dose, how it shipped, how long the vial has been open. Those are all things a buyer can check.

What it costs, and why people take the trade

Here is the reason the question exists, from every seller we track, verified on their own pages today:

From $69 a month against Novo's $349 pen and $149 tablet. For most people paying cash that gap, $2,400 to $3,400 a year, is the whole decision, and it is a reasonable one to make with eyes open. The seller check that makes it reasonable takes about ten minutes and is in how to check a GLP-1 seller; every verdict on our seller pages applies it.

The honest summary

Compounded semaglutide is as safe as the pharmacy that made it and the dose you were told to draw, and FDA's published concerns are a checklist for exactly those two things. It is not what FDA would choose for you, and it is what most cash buyers choose anyway, for a difference of several thousand dollars a year. If you take the trade, take it from a named, licensed pharmacy, at the label's dose, on the label's schedule, refrigerated, and throw the vial away at 28 days.

Sources5

FDA, concerns with unapproved GLP-1 drugs used for weight loss read Sep 3“FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 ... drugs, including semaglutide and tirzepatide, as an option for weight loss. This can be risky for patients, as unapproved versions do not undergo FDA's review for safety, effectiveness and quality before they are marketed. ... Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. ... A compounded drug might be appropriate if a patient's medical need cannot be met by an FDA-approved drug, or the FDA-approved drug is not commercially available. However, compounded drugs are not FDA approved.” ↩
FDA, dosing concerns with compounded semaglutide and tirzepatide read Sep 3“FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products. These dosing errors resulted from patients measuring and self-administering incorrect doses of the drug, and in some cases, health care professionals miscalculating doses of the drug. Additionally, the agency has received adverse event reports that may be related to patients prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label.” ↩
FDA, fraudulent compounded GLP-1 drugs, storage and multi-dose vials read Sep 3“FDA is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label. In some cases, the compounding pharmacies identified on the labels of the products do not exist. In other cases, the labels ... contain the name of a licensed pharmacy that, based on information FDA has gathered, did not compound these products. ... FDA has received complaints that certain compounded GLP-1 drugs have arrived warm or with inadequate ice packs ... The agency recommends patients not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration. ... Discard the vial within 28 days after the first use, even if medication remains in the vial. Do not continue using medication from the vial after 28 days, even if instructions from the compounder say the medication can be used for longer than 28 days.” ↩
FDA, Compounding and the FDA: Questions and Answers read Sep 3“Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. ... Generally, state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities. ... Facilities that register with FDA as outsourcing facilities under section 503B are primarily overseen by FDA and inspected by FDA according to a risk-based schedule. ... Drugs compounded in outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements. By contrast, drugs compounded by a licensed pharmacist in a state-licensed pharmacy ... in accordance with the conditions of section 503A of the FD&C Act, are not.” ↩
Ozempic.com read Sep 3“Only Novo Nordisk manufactures FDA-approved semaglutide medicines, like Ozempic.” ↩

Common questions

Is compounded semaglutide the same as Ozempic or Wegovy?

The same molecule, made by a licensed compounding pharmacy rather than Novo Nordisk. What differs is oversight: Wegovy and Ozempic went through FDA's review for safety, effectiveness and quality, and a compounded vial did not. Novo's own line is that only it makes FDA-approved semaglutide, which is true and does not mean the compounded molecule is different.

Is compounded semaglutide legal?

Yes. Compounding by a licensed pharmacist in a state-licensed pharmacy, or an FDA-registered outsourcing facility, is lawful with a prescription. FDA's position is that compounded drugs should be used only when an approved drug cannot meet a patient's medical need or is not commercially available, and it does not treat price as such a need.

What does FDA say about compounded semaglutide?

That it does not review compounded drugs for safety, effectiveness or quality before they are sold, and that it has received reports of dosing errors from self-measured vials, doses beyond the approved label, products shipped warm, and fraudulent products naming pharmacies that never made them. Its advice on multi-dose vials is to discard them 28 days after first use regardless of the compounder's instructions.

What is the difference between a 503A and 503B compounder?

A 503A pharmacy compounds per patient and is overseen by its state board of pharmacy, without FDA's manufacturing rules. A 503B outsourcing facility compounds in batches, is registered with and inspected by FDA, and must meet current good manufacturing practice, the same standard as a drug factory. Neither is FDA-approved, but 503B is the higher standard.

How do I check a compounded semaglutide seller?

Ask which pharmacy fills the prescription and look it up in that state's licence register; confirm the vial's concentration in mg per mL and your dose in both mg and units in writing; compare the escalation schedule to the Wegovy label's four weeks per step; refuse anything that arrives warm; and discard vials 28 days after first use. Our seller guide walks through it in about ten minutes.